NuCana plc (N04A.F)
| Chiusura precedente | 2,3800 |
| Aperto | 2,4200 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 2,4200 - 2,4200 |
| Intervallo di 52 settimane | 1,6400 - 5,4500 |
| Volume | |
| Media Volume | 77 |
| Capitalizzazione | 127,301M |
| Beta (5 anni mensile) | 0,66 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,9020 |
| Prossima data utili | 02 mar 2022 - 07 mar 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 1.138,60 |
- GlobeNewswire
NuCana Reports Third Quarter 2021 Financial Results and Provides Business Update
Enrolled Required Number of Patients to Conduct First Interim Analysis in Phase 3 Biliary Tract Cancer Study in the First Half of 2022 Received Fast Track Designation from FDA for Acelarin for the Treatment of Patients with Biliary Tract Cancer Announced Additional Encouraging Clinical Data for NUC-3373 and NUC-7738 at ESMO Multiple Near-Term Study Initiations and Data Announcements Expected EDINBURGH, United Kingdom, Nov. 18, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financia
- GlobeNewswire
NuCana to Present at the Jefferies 2021 London Healthcare Conference
EDINBURGH, United Kingdom, Nov. 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2021 London Healthcare Conference. Event: Jefferies 2021 London Healthcare ConferencePresentation Date: Wednesday, November 17, 2021Presentation Time: 4:20 PM GMT The presentation will be webcast live and available for replay under “Events & Presentatio
- GlobeNewswire
NuCana Appoints Elliott M. Levy, M.D. to its Board of Directors
Former Amgen SVP of Global Development and R&D Strategy and Operations Brings Substantial Drug Development Experience to NuCanaEDINBURGH, United Kingdom, Nov. 01, 2021 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer announced the appointment of Elliott M. Levy, M.D. to its Board of Directors. Dr. Levy brings over 20 years of experience at global pharmaceutical companies, inclu
